The molecular and cellular insight into the toxicology of bortezomib-induced peripheral neuropathy

Biomed Pharmacother. 2021 Oct:142:112068. doi: 10.1016/j.biopha.2021.112068. Epub 2021 Aug 24.

Abstract

The proteasome inhibitor bortezomib (BTZ) is a first-line antitumor drug, mainly used for multiple myeloma treatment. However, BTZ shows prominent toxicity in the peripheral nervous system, termed BTZ-induced peripheral neuropathy (BIPN). BIPN is characterized by neuropathic pain, resulting in a dose reduction or even treatment withdrawal. To date, the pathological mechanism of BIPN has not been elucidated. There is still no effective strategy to prevent or treat BIPN. This review summarizes the pathological mechanisms of BIPN, which involves the pathological changes of Schwann cells, neurons, astrocytes and macrophages. A better knowledge of the pathological mechanisms of BIPN would provide new ideas for therapeutic interventions of BIPN patients.

Keywords: Astrocytes; Bortezomib-induced peripheral neuropathy; Macrophages; Neurons; Pathological mechanisms; Schwann cells.

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / adverse effects*
  • Bortezomib / administration & dosage
  • Bortezomib / adverse effects*
  • Humans
  • Multiple Myeloma / drug therapy
  • Peripheral Nervous System Diseases / chemically induced*
  • Peripheral Nervous System Diseases / physiopathology
  • Proteasome Inhibitors / administration & dosage
  • Proteasome Inhibitors / adverse effects

Substances

  • Antineoplastic Agents
  • Proteasome Inhibitors
  • Bortezomib